Daclizumab Shows Promise in Multiple Sclerosis Trial Internal Medicine News Digital Network AMSTERDAM – Daclizumab reduced the rate of relapse and the rate of disability progression in patients with relapsing-remitting multiple sclerosis in a 1-year, placebo-controlled phase II trial . The novel immunomodulatory therapy also reduced the ... |
